Randomised, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Soluble Beta-1,3/1,6-Glucan (SBG) in Chronic Foot Ulcers in Patients With Diabetes.
Phase of Trial: Phase III
Latest Information Update: 07 Dec 2012
At a glance
- Drugs Soluble beta 1,3-1,6 glucan (Primary)
- Indications Diabetic foot ulcer
- Focus Registrational; Therapeutic Use
- 19 May 2011 New source identified and integrated (European Clinical Trials Database; EudraCT2008-003636-38).
- 23 Nov 2009 Status changed from active, no longer recruiting to completed, according to a Biotec Pharmacon media release.
- 23 Nov 2009 Primary endpoint 'Ulcer healing' has not been met.